Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Quetiapine
Drug ID BADD_D01888
Description Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder.[L8546] Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [Clozapine] and [Olanzapine].[A2189]
Indications and Usage Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546] Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.[A185438,A185447,T685]
Marketing Status approved
ATC Code N05AH04
DrugBank ID DB01224
KEGG ID D08456
MeSH ID D000069348
PubChem ID 5002
TTD Drug ID D0H7KF
NDC Product Code 0310-0530; 16729-145; 16729-149; 16714-453; 16714-454; 0093-8163; 50228-380; 0310-0280; 0310-0283; 60687-327; 65862-877; 68001-182; 68001-183; 68001-185; 80425-0107; 16729-146; 16729-150; 0310-0282; 60687-338; 63629-2479; 63629-2481; 65862-875; 70518-0752; 71093-136; 71205-402; 16729-147; 16714-455; 16714-457; 0093-8162; 42291-695; 42291-698; 42291-700; 43547-020; 0310-0272; 0310-0274; 0310-0278; 0310-0284; 68001-181; 70518-0239; 0310-0279; 60687-382; 65862-874; 71093-137; 0615-7987; 0310-0505; 43547-019; 50090-2830; 60687-349; 60687-371; 63629-2478; 63629-2480; 63629-2482; 63629-7116; 71093-138; 0615-7986; 0615-8119; 16714-452; 16714-456; 0093-8166; 33342-135; 43547-519; 71093-135; 72789-255; 80425-0143; 0093-2063; 0093-8164; 42291-699; 43547-520; 43547-522; 43547-523; 50090-2338; 50228-382; 50228-383; 0310-0271; 68001-184; 70518-0289; 71093-139; 16729-148; 29300-309; 50090-4788; 53002-1516; 0310-0275; 0310-0281; 60687-360; 65862-876; 70518-0570; 71205-026; 71610-702; 0310-0515; 0093-8165; 29300-308; 29300-310; 29300-311; 29300-312; 33342-136; 42291-696; 43547-021; 68001-180; 68788-7186; 70518-2828; 0615-7988; 0310-0520; 0310-0540; 33342-137; 42291-697; 43547-518; 43547-521; 50228-384; 65862-873; 71205-401; 0615-8118; 33342-134; 43547-022; 50228-381; 53002-1529
UNII BGL0JSY5SI
Synonyms Quetiapine Fumarate | Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt) | Seroquel | ICI 204,636 | ICI-204636 | ICI204636 | ICI 204636 | Quetiapine | 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
Chemical Information
Molecular Formula C21H25N3O2S
CAS Registry Number 111974-69-7
SMILES C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaemia neonatal18.04.03.002; 01.03.02.0110.000055%Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anger19.04.02.0010.001052%Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Angle closure glaucoma06.03.01.0010.000055%Not Available
Anticholinergic syndrome17.05.01.0010.000365%Not Available
Anuria20.01.03.0020.000082%Not Available
Anxiety19.06.02.0020.002556%
Apathy19.04.04.0020.000245%Not Available
Aphasia19.21.01.001; 17.02.03.0010.000229%
Aplasia pure red cell01.03.03.001; 10.02.01.0030.000055%Not Available
Apnoea22.02.01.0010.000082%
Apraxia19.21.01.002; 17.02.03.0020.000164%Not Available
Arrhythmia02.03.02.0010.000463%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Aspartate aminotransferase increased13.03.04.011--
Asphyxia22.02.02.001; 12.01.08.0110.000191%Not Available
Aspiration22.02.07.0070.000164%
Asthenia08.01.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Ataxia17.02.02.001; 08.01.02.0040.000218%
Atrial fibrillation02.03.03.002--
Atrioventricular block first degree02.03.01.004--
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.0100.000055%Not Available
Back pain15.03.04.005--
Benign prostatic hyperplasia21.04.02.0010.000055%Not Available
Bezoar07.11.01.0080.000436%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 26 Pages